Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

EVP and CFO

EVP, Commercial

CSO/EVP Disc & Trans Research

EVP Prod Dev & Med Aff & CMO

EVP, General Counsel & Sec

President and CEO

Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human monoclonal antibody against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines t...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-03-21	Premium	sold	Premium	Premium	Premium	-
2024-03-21	Premium	acquired	Premium	Premium	Premium	-
2024-02-23	Premium	acquired	Premium	Premium	Premium	EVP and CFO
2024-02-23	Premium	acquired	Premium	Premium	Premium	EVP, Commercial
2024-02-23	Premium	acquired	Premium	Premium	Premium	CSO/EVP Disc & Trans Research
2024-02-23	Premium	acquired	Premium	Premium	Premium	EVP Prod Dev & Med Aff & CMO
2024-02-23	Premium	acquired	Premium	Premium	Premium	EVP, General Counsel & Sec
2024-02-23	Premium	acquired	Premium	Premium	Premium	President and CEO
2024-02-23	Premium	sold	Premium	Premium	Premium	EVP, Commercial
2024-02-21	Premium	bought	Premium	Premium	Premium	-
2024-02-15	Premium	sold (taxes)	Premium	Premium	Premium	CSO/EVP Disc & Trans Research
2024-01-11	Premium	acquired	Premium	Premium	Premium	EVP and CFO
2024-01-11	Premium	sold (taxes)	Premium	Premium	Premium	EVP and CFO
2024-01-11	Premium	sold (taxes)	Premium	Premium	Premium	EVP, Commercial
2024-01-11	Premium	sold (taxes)	Premium	Premium	Premium	CSO/EVP Disc & Trans Research
2024-01-11	Premium	sold (taxes)	Premium	Premium	Premium	President and CEO
2024-01-11	Premium	sold (taxes)	Premium	Premium	Premium	EVP, General Counsel & Sec
2024-01-11	Premium	acquired	Premium	Premium	Premium	President and CEO
2024-01-11	Premium	acquired	Premium	Premium	Premium	EVP, General Counsel & Sec
2024-01-11	Premium	acquired	Premium	Premium	Premium	CSO/EVP Disc & Trans Research
2024-01-11	Premium	acquired	Premium	Premium	Premium	EVP, Commercial
2024-01-05	Premium	acquired	Premium	Premium	Premium	-
2024-01-05	Premium	acquired	Premium	Premium	Premium	-
2023-12-14	Premium	sold	Premium	Premium	Premium	EVP, Commercial
2023-12-14	Premium	acquired	Premium	Premium	Premium	EVP, Commercial

EXEL - Exelixis Inc Stock Price, Fair Value and News

Latest Insider Trading transactions for EXEL